{"filing":{"accession_number":"0001104659-26-092017","cik":"0001888886","ticker":"GPCR","company_name":"Structure Therapeutics Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2622407d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_8k.htm"},"events":[{"id":25436,"run_id":23088,"accession_number":"0001104659-26-092017","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Structure Therapeutics issued a press release on August 6, 2026 providing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $100.1 million, G\u0026A expenses of $18.6 million, and a net loss of $106.2 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosing material financial results.","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26266,"accession_number":"0001104659-26-092017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Structure Therapeutics issued a press release on August 6, 2026 providing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $100.1 million, G\u0026A expenses of $18.6 million, and a net loss of $106.2 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosing material financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:42.592607+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26266,"accession_number":"0001104659-26-092017","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Structure Therapeutics issued a press release on August 6, 2026 providing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $100.1 million, G\u0026A expenses of $18.6 million, and a net loss of $106.2 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosing material financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:42.592607+00:00","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-08-06"}]}